Searched the FDA website looking for a transcript of the ODAC panel meeting. Does anyone know if a transcript is available? Greg did mention in the conference call that the leukemia experts on the panel were pretty positive on the efficacy profile of the drug. Just wanting to find a bit more info on this matter.
As I understand, ODAC were not concerned with the efficacy and safety issue, simply because the diagnostic matter is what they were focussing on at this particular meeting. The fact they did not mention the other issues at this time is not necessarily a positive for the application. Is this the interpretation of other investors out there?
Ann: Change in substantial holding , page-5
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)